{"preliminary_commentary":{"by_channel":{"youtube":11,"x_thread":10,"podcast":6,"bluesky_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04915755\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"ZEST","nct_id":"NCT04915755","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=zest-nct04915755. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ZEST","arms":[{"description":"Eligible participants will receive either Niraparib or Placebo.","label":"Cohort1:Participants with tBRCAmut HER2-breast cancer(Independent of HR status,including HR+andTNBC)","type":"EXPERIMENTAL"},{"description":"Eligible participants will receive either Niraparib or Placebo.","label":"Cohort 2: Participants with tBRCAwt TNBC","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-12-31","type":"ESTIMATED"},"conditions":["Neoplasms, Breast"],"enrollment":{"count":40,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Niraparib","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2025-07-16","lead_sponsor":"GlaxoSmithKline","official_title":"A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-06-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Treatment Emergent Adverse Event (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)","timeFrame":"Up to approximately 125 weeks"},{"measure":"Number of Participants With TEAEs Leading to Death","timeFrame":"Up to approximately 125 weeks"},{"measure":"Number of Participants With TEAEs Leading to Dose Modifications and Discontinuation of Study Treatment","timeFrame":"Up to approximately 125 weeks"},{"measure":"Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status","timeFrame":"Up to approximately 125 weeks"},{"measure":"Number of Participants With Worst-Case Post-Baseline (WCPB) Hematology Results Relative to Baseline","timeFrame":"Up to approximately 125 weeks"},{"measure":"Number of Participants With Worst-Case Post-Baseline (WCPB) Clinical Chemistry Results Relative to Baseline","timeFrame":"Up to approximately 125 weeks"},{"measure":"Number of Participants With Worst-Case Post-Baseline (WCPB) Vital Signs Results Relative to Baseline","timeFrame":"Up to approximately 125 weeks"},{"measure":"Number of Participants With Use of Concomitant Medications","timeFrame":"Up to approximately 125 weeks"}],"references":[],"start_date":{"date":"2021-06-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease","url":"https://clinicaltrials.gov/study/NCT04915755"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/zest-nct04915755"}